{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:12:38Z","timestamp":1794485558594,"version":"4.9.1"},"reference-count":303,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.autrev.2024.103581","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:21:04Z","timestamp":1722032464000},"page":"103581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus"],"prefix":"10.1016","volume":"23","author":[{"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Barilaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bearzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Biaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukas","family":"Chatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Colafrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Corberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Currado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"D'Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saviana","family":"Gandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Genovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Daniela","family":"Grembiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Salvatore","family":"Iaquinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menelaos N.","family":"Manoussakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Naty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Occhialini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Orefice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pontarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Priori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Rivellese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Triolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trunfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingran","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103581_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2016.03.002","article-title":"Shaping the spectrum - from autoinflammation to autoimmunity","volume":"165","author":"Hedrich","year":"2016","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41584-021-00652-9","article-title":"Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases","volume":"17","author":"Szekanecz","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102469","article-title":"Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: a comprehensive review","volume":"19","author":"Lee","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103356","article-title":"Autoantibodies testing in autoimmunity: diagnostic, prognostic and classification value","volume":"22","author":"Sciascia","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103386","article-title":"Functional autoantibodies: definition, mechanisms, origin and contributions to autoimmune and non-autoimmune disorders","volume":"22","author":"Yu","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0035","doi-asserted-by":"crossref","first-page":"102774","DOI":"10.1016\/j.autrev.2021.102774","article-title":"Systemic autoinflammatory disease in adults","volume":"20","author":"Betrains","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41584-023-01063-8","article-title":"New genes, pathways and therapeutic targets in autoinflammatory diseases","volume":"20","author":"Papa","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.06.010","article-title":"Inflammasomes and autoimmune and rheumatic diseases: a comprehensive review","volume":"103","author":"Shin","year":"2019","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103312","article-title":"Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders","volume":"22","author":"Konen","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0055","doi-asserted-by":"crossref","first-page":"102399","DOI":"10.1016\/j.autrev.2019.102399","article-title":"Can we wean patients with inflammatory arthritis from biological therapies?","volume":"18","author":"Edwards","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"9894","key":"10.1016\/j.autrev.2024.103581_bb0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103581_bb0065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1741-7015-11-100","article-title":"Requirements for innate immune pathways in environmentally induced autoimmunity","volume":"11","author":"Pollard","year":"2013","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41584-022-00904-2","article-title":"A path towards personalized medicine for autoinflammatory and related diseases","volume":"19","author":"Miner","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0075","doi-asserted-by":"crossref","first-page":"103496","DOI":"10.1016\/j.autrev.2023.103496","article-title":"Machine learning application in autoimmune diseases: state of art and future prospectives","volume":"23","author":"Danieli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103581_bb0080","article-title":"A strategy towards disentangling treatment refractory from misdiagnosed axial Spondyloarthritis","author":"McGonagle","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0085","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: towards patient-centric precision medicine","volume":"16","author":"Pitzalis","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0090","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41584-022-00845-w","article-title":"Precision medicine: the precision gap in rheumatic disease","volume":"18","author":"Lin","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0095","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0105","doi-asserted-by":"crossref","first-page":"102738","DOI":"10.1016\/j.autrev.2020.102738","article-title":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019 Consensus","volume":"20","author":"Giacomelli","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","article-title":"Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study","volume":"77","author":"Akdemir","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-022-02851-5","article-title":"Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data","volume":"24","author":"Duong","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-018-1520-4","article-title":"Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes","volume":"20","author":"de Moel","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0130","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar4439","article-title":"ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial","volume":"16","author":"Seegobin","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb0135","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3899\/jrheum.131401","article-title":"Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen","volume":"41","author":"Ma","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03009742.2018.1466362","article-title":"Anti-cyclic citrullinated peptide antibodies, 28-joint disease activity score, and magnetic resonance imaging bone oedema at baseline predict 11 years\u2019 functional and radiographic outcome in early rheumatoid arthritis","volume":"48","author":"Hetland","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0145","first-page":"1065","article-title":"Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials","volume":"34","author":"Levitsky","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0155","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40744-019-00174-7","article-title":"Efficacy of abatacept and adalimumab in patients with early rheumatoid arthritis with multiple poor prognostic factors: post hoc analysis of a Randomized Controlled Clinical Trial (AMPLE)","volume":"6","author":"Fleischmann","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb0170","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2018-213502","article-title":"Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0175","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10067-016-3489-1","article-title":"Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial","volume":"36","author":"\u00d8rnbjerg","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0180","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/annrheumdis-2018-213035","article-title":"Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors","volume":"77","author":"Teitsma","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13075-019-1968-x","article-title":"Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged <65years and those \u226565years of age","volume":"21","author":"Tesser","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-017-1484-9","article-title":"Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial","volume":"20","author":"Smolen","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s42358-021-00213-4","article-title":"Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis","volume":"61","author":"de la Vega","year":"2021","journal-title":"Adv Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3899\/jrheum.120715","article-title":"Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR trial","volume":"40","author":"Curtis","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10753-012-9544-4","article-title":"Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis","volume":"36","author":"Pappas","year":"2013","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0210","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/ar4504","article-title":"Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis","volume":"16","author":"M\u00e1rquez","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb0215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/FPC.0000000000000140","article-title":"Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study","volume":"25","author":"Canet","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/kev258","article-title":"Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis","volume":"55","author":"Burmester","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002570","article-title":"Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review","volume":"8","author":"Wientjes","year":"2022","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0230","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00296-016-3476-5","article-title":"Associations between PTPRC rs10919563 A\/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis","volume":"36","author":"Lee","year":"2016","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/tpj.2017.26","article-title":"Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis","volume":"17","author":"Bek","year":"2017","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213073","article-title":"Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept","volume":"14","author":"Ferreiro-Iglesias","year":"2019","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.37707","article-title":"The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers","volume":"65","author":"Fabris","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0250","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/cei.12696","article-title":"Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy","volume":"182","author":"Iwaszko","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/FPC.0000000000000446","article-title":"Association between nuclear factor of activated T cells C2 polymorphisms and treatment response in rheumatoid arthritis patients receiving tumor necrosis factor-alpha inhibitors","volume":"32","author":"Kim","year":"2022","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0260","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41397-018-0057-x","article-title":"Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients","volume":"19","author":"Canet","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0265","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3109\/s10165-012-0699-5","article-title":"Association between tumor necrosis factor-\u03b1 (TNF-\u03b1) promoter \u2212308 G\/A and response to TNF-\u03b1 blockers in rheumatoid arthritis: a meta-analysis","volume":"23","author":"Zeng","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003394","article-title":"Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis","volume":"9","author":"Cui","year":"2013","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0000000000000013","article-title":"Confirmation of -174G\/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome","volume":"24","author":"D\u00e1vila-Fajardo","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0280","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-014-3015-1","article-title":"Functional FCGR3A 158 V\/F and IL-6 -174 C\/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis","volume":"34","author":"Lee","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103581_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672255","article-title":"Validation of GWAS-identified variants for anti-TNF drug response in rheumatoid arthritis: a meta-analysis of two large cohorts","volume":"12","author":"S\u00e1nchez-Maldonado","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0290","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41397-019-0072-6","article-title":"A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients","volume":"19","author":"Luxembourger","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb0295","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/genes13071284","article-title":"Genetic biomarkers as predictors of response to tocilizumab in rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Janahiraman","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.autrev.2024.103581_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109184","article-title":"Associations between the interleukin-6 rs1800795 G\/C and interleukin-6 receptor rs12083537 a\/G polymorphisms and response to disease-modifying antirheumatic drugs in rheumatoid arthritis: a meta-analysis","volume":"112","author":"Lee","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-016-1085-z","article-title":"Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?","volume":"18","author":"Cuppen","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/mr\/roab128","article-title":"The implication of long non-coding RNA expression profile in rheumatoid arthritis: correlation with treatment response to tumor necrosis factor inhibitor","volume":"33","author":"Wang","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0315","author":"Krintel"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0320","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.170266","article-title":"Plasma MicroRNA profiles in patients with early rheumatoid arthritis responding to adalimumab plus methotrexate vs methotrexate alone: a placebo-controlled clinical trial","volume":"45","author":"Sode","year":"2018","journal-title":"J Rheumatol"},{"issue":"21","key":"10.1016\/j.autrev.2024.103581_bb0325","doi-asserted-by":"crossref","first-page":"12989","DOI":"10.3390\/ijms232112989","article-title":"miRNA-mediated epigenetic regulation of treatment response in RA patients-a systematic review","volume":"23","author":"Mucientes","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103581_bb0330","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-016-1052-8","article-title":"Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study","volume":"18","author":"Nakamura","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0335","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13075-019-1999-3","article-title":"Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor","volume":"21","author":"Farutin","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14397595.2019.1602242","article-title":"Expressions of circadian clock genes represent disease activities of RA patients treated with biological DMARDs","volume":"30","author":"Kaneshiro","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0345","first-page":"1","article-title":"Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis","author":"Curtis","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113937","article-title":"Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients","volume":"9","author":"MacIsaac","year":"2014","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237143","article-title":"Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis","volume":"15","author":"Derambure","year":"2020","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0360","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10067-014-2547-9","article-title":"Meta-analysis of gene expression profiles to predict response to biologic agents in rheumatoid arthritis","volume":"33","author":"Lee","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0365","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","article-title":"CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic \u2018window of opportunity\u2019","volume":"16","author":"Greisen","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0370","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10067-016-3467-7","article-title":"Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study","volume":"36","author":"Johnson","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0375","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/03009742.2017.1309061","article-title":"all Society for Rheumatology Research Utrecht (SRU) investigators. Proteomics to predict the response to tumour necrosis factor-\u03b1 inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score","volume":"47","author":"Cuppen","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0380","first-page":"367","article-title":"Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis","volume":"37","author":"Tweehuysen","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0385","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13075-021-02547-2","article-title":"Serum TNF\u03b1 levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study","volume":"23","author":"Miyazaki","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"28","key":"10.1016\/j.autrev.2024.103581_bb0390","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026592","article-title":"Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA): a multicenter RA ultrasound prospective cohort in Japan","volume":"100","author":"Kawashiri","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-021-02556-1","article-title":"Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial","volume":"23","author":"Stockfelt","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0400","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13075-016-1132-9","article-title":"Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY","volume":"18","author":"Boyapati","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0405","first-page":"94","article-title":"Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis","volume":"36","author":"Siebuhr","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0410","first-page":"829","article-title":"Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis","volume":"36","author":"Gudmann","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0415","first-page":"568","volume":"36","author":"Juhl","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0420","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/14397595.2017.1370766","article-title":"Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis","volume":"28","author":"Aizu","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0425","doi-asserted-by":"crossref","first-page":"13975","DOI":"10.1038\/s41598-020-70942-x","article-title":"Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis","volume":"10","author":"Blair","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-020-02378-7","article-title":"Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study","volume":"23","author":"Drobinski","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103581_bb0435","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/487230","article-title":"Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients","volume":"2015","author":"Lee","year":"2015","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0440","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/14397595.2019.1621026","article-title":"Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: a post hocanalysis of the SURPRISE study","volume":"30","author":"Kato","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0445","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","article-title":"Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study","volume":"18","author":"Bay-Jensen","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0450","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/14397595.2014.958893","article-title":"A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study","volume":"25","author":"Hirata","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0455","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10067-016-3479-3","article-title":"Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission","volume":"36","author":"Nakajima","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0460","doi-asserted-by":"crossref","first-page":"113971","DOI":"10.1016\/j.jpba.2021.113971","article-title":"Metabolomic profiling reveals plasma GlycA and GlycB as a potential biomarkers for treatment efficiency in rheumatoid arthritis","volume":"197","author":"Dudka","year":"2021","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0465","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/jpm12061003","article-title":"IL-10 induced by mTNF crosslinking-mediated reverse signaling in a whole blood assay is predictive of response to TNFi therapy in rheumatoid arthritis","volume":"12","author":"Krasselt","year":"2022","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0470","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12891-021-04392-5","article-title":"Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan","volume":"22","author":"Kawashiri","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0475","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002683","article-title":"Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis","volume":"8","author":"Wu","year":"2022","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145468","article-title":"Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Na\u00efve patients with rheumatoid arthritis: a single-center prospective study at 1 year (the Keio first-bio cohort study)","volume":"10","author":"Izumi","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0485","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-020-02163-6","article-title":"Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes","volume":"22","author":"Gabay","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0490","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ijms24010321","article-title":"In contrast to anti-CCP, MMP-degraded and citrullinated vimentin (VICM) is both a diagnostic and a treatment response biomarker","volume":"24","author":"Drobinski","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0495","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0500","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","article-title":"ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis","volume":"108","author":"Bui","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0505","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.51.3.364","article-title":"B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue","volume":"51","author":"Carlsen","year":"2002","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0510","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/03009742.2013.834964","article-title":"Etanercept decreases synovial expression of tumour necrosis factor-\u03b1 and lymphotoxin-\u03b1 in rheumatoid arthritis","volume":"43","author":"Nereg\u00e5rd","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0515","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0520","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/1756-185X.12197","article-title":"Zymographic analysis using gelatin-coated film of the effect of etanercept on the extracellular matrix-degrading activity in synovial fluids of rheumatoid arthritis patients","volume":"19","author":"Kamataki","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197001","article-title":"Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: a pilot study","volume":"13","author":"Andersen","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2024.103581_bb0530","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13075-016-0919-z","article-title":"Higher expression of TNF\u03b1-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy","volume":"18","author":"De Groof","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103581_bb0535","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fimmu.2019.01459","article-title":"A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis","volume":"10","author":"Aterido","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0540","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/annrheumdis-2013-204417","article-title":"Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy","volume":"73","author":"Das","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0545","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/art.42295","article-title":"Synovial inflammatory pathways characterize anti-TNF-responsive rheumatoid arthritis patients","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"10271","key":"10.1016\/j.autrev.2024.103581_bb0550","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"R4RA collaborative group. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0555","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0560","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"10.1016\/j.autrev.2024.103581_bb0565","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0570","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0575","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2024.103581_bb0580","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/ar830","article-title":"A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus","volume":"5","author":"Eisenberg","year":"2003","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0585","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0590","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0595","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/03009740410010227","article-title":"Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone","volume":"33","author":"van Vollenhoven","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0600","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0605","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0610","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.clim.2007.11.012","article-title":"A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery","volume":"126","author":"Sutter","year":"2008","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0615","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/ard.2008.091124","article-title":"Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases","volume":"67","author":"Lu","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0620","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/peds.2008-2361","article-title":"B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus","volume":"123","author":"Kumar","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0625","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0961203308094653","article-title":"Effects of rituximab on resistant SLE disease including lung involvement","volume":"18","author":"Reynolds","year":"2009","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0630","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb0635","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0640","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0645","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0650","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.autrev.2024.103581_bb0655","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0660","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb0665","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0670","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb0675","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb0680","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/art.40511","article-title":"Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0685","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0690","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0695","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0700","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb0705","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of Iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0710","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0715","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0720","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0725","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0730","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0735","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"10289","key":"10.1016\/j.autrev.2024.103581_bb0740","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0745","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0750","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0755","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0760","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0765","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.autrev.2024.103581_bb0770","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0775","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0780","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tripleo.2010.02.032","article-title":"Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sj\u00f6gren patients: a prospective sample study","volume":"110","author":"Cankaya","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0785","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide-hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb0790","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0795","first-page":"443","article-title":"Efficacy of retreatment with rituximab in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"33","author":"Meiners","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0800","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb0805","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0810","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0815","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb0820","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"10320","key":"10.1016\/j.autrev.2024.103581_bb0825","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.autrev.2024.103581_bb0830","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0835","first-page":"96","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet","volume":"9","author":"Highland","year":"2021","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0840","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100weeks: data from a randomized controlled trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0845","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0850","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0855","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0860","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0865","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease","volume":"63","author":"Roth","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0870","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0875","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.41627","article-title":"Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis-related interstitial lung disease","volume":"73","author":"Assassi","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0880","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.autrev.2017.07.017","article-title":"How I treat patients with adult onset Still\u2019s disease in clinical practice","volume":"16","author":"Govoni","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb0885","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1093\/rheumatology\/keab485","article-title":"Current and emerging biological therapy in adult-onset Still\u2019s disease","volume":"60","author":"Ma","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2024.103581_bb0890","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14712598.2024.2307340","article-title":"The latest advances in the use of biological DMARDs to treat Still\u2019s disease","volume":"24","author":"Di Cola","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2024.103581_bb0895","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2023-0995","article-title":"Systematic review and meta-analysis of pharmacological interventions in adult-onset Still\u2019s disease highlights the beneficial role of biologic DMARDs","author":"Ruscitti","year":"2024","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0900","doi-asserted-by":"crossref","first-page":"103400","DOI":"10.1016\/j.autrev.2023.103400","article-title":"Expert consensus on the treatment of patients with adult-onset still\u2019s disease with the goal of achieving an early and long-term remission","volume":"22","author":"Giacomelli","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb0905","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still\u2019s disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0910","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb0915","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of Adult-Onset Still\u2019s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb0920","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb0925","first-page":"840","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0930","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0935","doi-asserted-by":"crossref","first-page":"187","DOI":"10.55563\/clinexprheumatol\/fsq5vq","article-title":"The treatment of adult-onset Still\u2019s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature","volume":"39","author":"Giacomelli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0940","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20933133","article-title":"The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still\u2019s disease. A systematic review and meta-analysis of observational studies","volume":"12","author":"Ruscitti","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2024.103581_bb0945","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211059598","article-title":"Update on the therapy of adult-onset Still\u2019s disease with a focus on IL-1-inhibition: a systematic review","volume":"13","author":"Kedor","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb0950","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb0955","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb0960","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/jcm11020430","article-title":"The role of interleukin 18\/interleukin 18-binding protein in adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis","volume":"11","author":"Girard-Guyonvarc\u2019h","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb0965","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214496","article-title":"Prolonged treatment with Tadekinig alfa in adult-onset Still\u2019s disease","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb0970","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease","volume":"19","author":"Casta\u00f1eda","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl. 6","key":"10.1016\/j.autrev.2024.103581_bb0975","article-title":"Anakinra in children and adults with Still\u2019s disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb0980","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb0985","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still\u2019s disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb0990","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103581_bb0995","doi-asserted-by":"crossref","first-page":"101632","DOI":"10.1016\/j.smim.2022.101632","article-title":"The clinical heterogeneity of adult onset Still\u2019s disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients","volume":"58","author":"Ruscitti","year":"2021","journal-title":"Semin Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1000","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.3390\/jcm10122633","article-title":"Clinical phenotypes of adult-onset Still\u2019s disease: new insights from pathophysiology and literature findings","volume":"10","author":"Mitrovic","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb1005","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1093\/rheumatology\/keaa904","article-title":"Dissecting the clinical heterogeneity of adult-onset Still\u2019s disease: results from a multi-dimensional characterization and stratification","volume":"60","author":"Berardicurti","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb1010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/1744666X.2018.1533403","article-title":"Pathogenesis of adult onset still\u2019s disease: current understanding and new insights","volume":"14","author":"Ruscitti","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb1015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","article-title":"Biologic drugs in adult onset Still\u2019s disease: a systematic review and meta-analysis of observational studies","volume":"13","author":"Ruscitti","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"15","key":"10.1016\/j.autrev.2024.103581_bb1020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015123","article-title":"Managing adult-onset Still\u2019s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study","volume":"98","author":"Ruscitti","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/1744666X.2018.1465821","article-title":"Complications of adult-onset Still\u2019s disease and their management","volume":"14","author":"Mitrovic","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2016.09.016","article-title":"Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers","volume":"16","author":"Ruscitti","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-020-02245-5","article-title":"Parenchymal lung disease in adult onset Still\u2019s disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients","volume":"22","author":"Ruscitti","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1040","first-page":"23","article-title":"Adult-onset Still\u2019s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse","volume":"37 Suppl 121","author":"Takakuwa","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"30","key":"10.1016\/j.autrev.2024.103581_bb1045","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004258","article-title":"Parenchymal lung involvement in adult-onset still disease: a STROBE-compliant case series and literature review","volume":"95","author":"Gerfaud-Valentin","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"9927","key":"10.1016\/j.autrev.2024.103581_bb1050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-00571-1","article-title":"Immune cartography of macrophage activation syndrome in the COVID-19 era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1060","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb1065","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","article-title":"Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"78","author":"Minoia","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1075","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3899\/jrheum.170955","article-title":"Macrophage activation syndrome in patients affected by adult-onset still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale cohort","volume":"45","author":"Ruscitti","year":"2018","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1080","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature","volume":"45","author":"Lenert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1085","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/mr\/roab119","article-title":"Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome","volume":"32","author":"Wu","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb1090","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s10067-022-06184-1","article-title":"Short-term, low-dose etoposide in refractory adult-onset Still\u2019s disease-associated macrophage activation syndrome","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb1095","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J Rheumatol"},{"issue":"19","key":"10.1016\/j.autrev.2024.103581_bb1100","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1110","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hoc.2015.06.011","article-title":"The role of hematopoietic stem cell transplantation in treatment of hemophagocytic lymphohistiocytosis","volume":"29","author":"Nikiforow","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1115","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb1120","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb1125","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2020-218048","article-title":"Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences","volume":"79","author":"Ruscitti","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb1130","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.42137","article-title":"The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis","volume":"74","author":"Binstadt","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","article-title":"New markers for adult-onset Still\u2019s disease","volume":"85","author":"Mitrovic","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1140","first-page":"322","article-title":"Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease","volume":"28","author":"Fautrel","year":"2001","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-010-1601-4","article-title":"Clinical features and hyperferritinemia diagnostic cutoff points for AOSD based on ROC curve: a Chinese experience","volume":"32","author":"Lian","year":"2012","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb1155","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s10067-021-05722-7","article-title":"Identification of prognostic factors and construction of a nomogram for patients with relapse\/refractory adult-onset Still\u2019s disease","volume":"40","author":"Yin","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1160","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10067-020-05266-2","article-title":"Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still\u2019s disease","volume":"40","author":"Kim","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155642","article-title":"Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still\u2019s disease: a prospective cohort study","volume":"146","author":"Zhang","year":"2021","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb1170","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/acr.22194","article-title":"Clinical manifestations of adult-onset Still\u2019s disease presenting with erosive arthritis: association with low levels of ferritin and Interleukin-18","volume":"66","author":"Ichida","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103114","article-title":"Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications","volume":"21","author":"Ruscitti","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103309","article-title":"The similar expression of both ferritin and scavenger receptors activation genes in patients with COVID19 and AOSD support their role in the pathogenesis of these diseases and identify a common mechanism at the basis of the \u201chyperferritinemic syndromes\u201d","volume":"22","author":"Berardicurti","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1185","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.130575","article-title":"Interleukin 18: a biomarker for differential diagnosis between adult-onset Still\u2019s disease and sepsis","volume":"41","author":"Priori","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb1190","article-title":"IL-18 serum level in adult onset Still\u2019s disease: a marker of disease activity","volume":"2012","author":"Colafrancesco","year":"2012","journal-title":"Int J Inflam"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb1195","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still\u2019s disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1200","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still\u2019s disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1205","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103581_bb1210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750114","article-title":"Usefulness of Interleukin-18 as a diagnostic biomarker to differentiate adult-onset Still\u2019s disease with\/without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults","volume":"12","author":"Shiga","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1215","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/rheumatology\/keaa634","article-title":"Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis","volume":"60","author":"Mizuta","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/03009742.2013.824023","article-title":"Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still\u2019s disease","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103581_bb1225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103581_bb1230","article-title":"Interleukin-18 is a potential biomarker to discriminate active adult-onset Still\u2019s disease from COVID-19","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1235","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/art.24137","article-title":"S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin","volume":"58","author":"Wittkowski","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"19","key":"10.1016\/j.autrev.2024.103581_bb1240","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.3390\/jcm10194400","article-title":"Distinct effects of interleukin-1\u03b2 inhibition upon cytokine profile in patients with adult-onset Still\u2019s disease and active articular manifestation responding to canakinumab","volume":"10","author":"Ghannam","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-020-0398-2","article-title":"The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis","volume":"18","author":"Aljaberi","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1250","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3899\/jrheum.140651","article-title":"Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still\u2019s disease","volume":"41","author":"Bae","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12969-021-00660-9","article-title":"Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study","volume":"19","author":"Qu","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb1260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235326","article-title":"Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still\u2019s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort","volume":"15","author":"Di Benedetto","year":"2020","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1265","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/jcm11010206","article-title":"Detection and prediction of macrophage activation syndrome in Still\u2019s disease","volume":"11","author":"Javaux","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1270","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103581_bb1280","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keac247","article-title":"Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still\u2019s disease","volume":"62","author":"Ruscitti","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103581_bb1295","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2024.103581_bb1300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpeds.2021.02.008","article-title":"Sudden hypotension and increased serum interferon-\u03b3 and interleukin-10 predict early macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"235","author":"Guo","year":"2021","journal-title":"J Pediatr"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb1305","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3","volume":"54","author":"Put","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.autrev.2024.103581_bb1310","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.autrev.2024.103581_bb1315","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.autrev.2024.103581_bb1320","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1325","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1330","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb1335","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103581_bb1340","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10349","key":"10.1016\/j.autrev.2024.103581_bb1345","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1355","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1360","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1365","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jdv.13884","article-title":"Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Mostafa","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1370","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","article-title":"Adipose tissue as an endocrine organ","volume":"316","author":"Galic","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03009742.2014.962081","article-title":"Two-year survival rates of anti-TNF-\u03b1 therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA","volume":"44","author":"Iannone","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103581_bb1380","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","article-title":"Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study","volume":"40","author":"Lorenzin","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"10162","key":"10.1016\/j.autrev.2024.103581_bb1385","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2024.103581_bb1390","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1395","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keab543","article-title":"Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12weeks in patients with active ankylosing spondylitis (TORTUGA trial)","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103581_bb1400","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103581_bb1405","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1745-6215-10-43","article-title":"Dealing with heterogeneity of treatment effects: is the literature up to the challenge?","volume":"10","author":"Gabler","year":"2009","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.autrev.2024.103581_bb1410","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.298.10.1209","article-title":"Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification","volume":"298","author":"Kent","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.autrev.2024.103581_bb1415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0895-4356(98)00006-7","article-title":"Clinical versus statistical considerations in the design and analysis of clinical research","volume":"51","author":"Horwitz","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1420","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12874-017-0466-6","article-title":"Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature","volume":"18","author":"Dahan","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"4 Suppl 1","key":"10.1016\/j.autrev.2024.103581_bb1425","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2007.02.002","article-title":"Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment","volume":"120","author":"Greenfield","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2024.103581_bb1430","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1745-6215-11-85","article-title":"Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal","volume":"11","author":"Kent","year":"2010","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1435","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","article-title":"Real-world data: a brief review of the methods, applications, challenges and opportunities","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103581_bb1440","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1445","article-title":"Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study","volume":"1","author":"Toews","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"SI3","key":"10.1016\/j.autrev.2024.103581_bb1450","article-title":"Introducing data sciences to N-of-1 designs, statistics, use-cases, the future, and the Moniker \u2019N-of-1\u2032 trial","volume":"4","author":"Davidson","year":"2022","journal-title":"Harv Data Sci Rev"},{"issue":"SI3","key":"10.1016\/j.autrev.2024.103581_bb1455","article-title":"Personalized data science and personalized (N-of-1) trials: promising paradigms for individualized health care","volume":"4","author":"Duan","year":"2022","journal-title":"Harv Data Sci Rev"},{"issue":"8 Suppl","key":"10.1016\/j.autrev.2024.103581_bb1460","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.jclinepi.2013.04.006","article-title":"Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research","volume":"66","author":"Duan","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"9454","key":"10.1016\/j.autrev.2024.103581_bb1465","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1470","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"10.1016\/j.autrev.2024.103581_bb1475","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/sim.1296","article-title":"Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems","volume":"21","author":"Pocock","year":"2002","journal-title":"Stat Med"},{"issue":"9209","key":"10.1016\/j.autrev.2024.103581_bb1480","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.autrev.2024.103581_bb1485","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198604033141406","article-title":"Determining optimal therapy--randomized trials in individual patients","volume":"314","author":"Guyatt","year":"1986","journal-title":"N Engl J Med"},{"issue":"7472","key":"10.1016\/j.autrev.2024.103581_bb1490","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/bmj.329.7472.966","article-title":"Individual response to treatment: is it a valid assumption?","volume":"329","author":"Senn","year":"2004","journal-title":"BMJ"},{"issue":"SI3","key":"10.1016\/j.autrev.2024.103581_bb1495","article-title":"Conduct and implementation of personalized trials in research and practice","volume":"4","author":"Kravitz","year":"2022","journal-title":"Harv Data Sci Rev"},{"key":"10.1016\/j.autrev.2024.103581_bb1500","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2147\/JMDH.S262776","article-title":"Harnessing real-world data for regulatory use and applying innovative applications","volume":"13","author":"Zou","year":"2020","journal-title":"J Multidiscip Healthc"},{"issue":"5","key":"10.1016\/j.autrev.2024.103581_bb1505","doi-asserted-by":"crossref","first-page":"743","DOI":"10.21037\/hbsn-23-435","article-title":"Expert consensus-promoting clinical excellence and ultimately benefitting patients","volume":"12","author":"Chen","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"12","key":"10.1016\/j.autrev.2024.103581_bb1510","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1016\/j.arthro.2018.10.004","article-title":"Research pearls: expert consensus based evidence using the Delphi method","volume":"34","author":"Hohmann","year":"2018","journal-title":"Arthroscopy"},{"issue":"3","key":"10.1016\/j.autrev.2024.103581_bb1515","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103581_bb1520","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.sapharm.2021.06.027","article-title":"\u2018More of an art than a science\u2019? The development, design and mechanics of the Delphi technique","volume":"18","author":"Drumm","year":"2022","journal-title":"Res Social Adm Pharm"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T12:54:07Z","timestamp":1725454447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":303,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1568997224000727"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103581","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103581"}}